Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia - PubMed (original) (raw)
. 2012 Mar 1;30(7):742-50.
doi: 10.1200/JCO.2011.39.2092. Epub 2012 Jan 30.
Klaus H Metzeler, Sebastian Schwind, Heiko Becker, Kati Maharry, Krzysztof Mrózek, Michael D Radmacher, Jessica Kohlschmidt, Deedra Nicolet, Susan P Whitman, Yue-Zhong Wu, Bayard L Powell, Thomas H Carter, Jonathan E Kolitz, Meir Wetzler, Andrew J Carroll, Maria R Baer, Joseph O Moore, Michael A Caligiuri, Richard A Larson, Clara D Bloomfield
Affiliations
- PMID: 22291079
- PMCID: PMC3295550
- DOI: 10.1200/JCO.2011.39.2092
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia
Guido Marcucci et al. J Clin Oncol. 2012.
Abstract
Purpose: To determine the frequency of DNMT3A mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene- and microRNA-expression signatures in primary cytogenetically normal acute myeloid leukemia (CN-AML).
Patients and methods: Four hundred fifteen previously untreated adults were analyzed for DNMT3A mutations and established prognostic gene mutations and expression markers. Gene- and microRNA-expression profiles were derived using microarrays.
Results: Younger (< 60 years; n = 181) and older (≥ 60 years; n = 234) patients had similar frequencies of DNMT3A mutations (35.3% v 33.3%). Missense mutations affecting arginine codon 882 (R882-DNMT3A) were more common (n = 92; 62%) than those affecting other codons (non-R882-DNMT3A). DNMT3A-mutated patients did not differ regarding complete remission rate, but had shorter disease-free survival (DFS; P = .03) and, by trend, overall survival (OS; P = .07) than DNMT3A-wild-type patients. In multivariable analyses, DNMT3A mutations remained associated with shorter DFS (P = .01), but not with shorter OS. When analyzed separately, the two DNMT3A mutation types had different significance by age group. Younger patients with non-R882-DNMT3A mutations had shorter DFS (P = .002) and OS (P = .02), whereas older patients with R882-DNMT3A mutations had shorter DFS (P = .005) and OS (P = .002) after adjustment for other clinical and molecular prognosticators. Gene- and microRNA-expression signatures did not accurately predict DNMT3A mutational status.
Conclusion: DNMT3A mutations are frequent in CN-AML, and their clinical significance seems to be age dependent. DNMT3A-R882 mutations are associated with adverse prognosis in older patients, and non-R882-DNMT3A mutations are associated with adverse prognosis in younger patients. Low accuracy of gene- and microRNA-expression signatures in predicting DNMT3A mutation status suggested that the role of these mutations in AML remains to be elucidated.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
Fig 1.
Age group–adjusted clinical outcome for patients with and without DNMT3A mutations. (A) Disease-free survival. (B) Overall survival. The curves are adjusted for age group. wt, wild type.
Fig 2.
Kaplan-Meier survival curves according to DNMT3A mutation type (R882-DNMT3A v non–R882-DNMT3A mutations v DNMT3A wild type). (A) Disease-free survival and (B) overall survival of younger (< 60 years) patients. (C) Disease-free survival and (D) overall survival of older (≥ 60 years) patients. mut, mutated; wt, wild type.
Similar articles
- Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
Bhatnagar B, Eisfeld AK, Nicolet D, Mrózek K, Blachly JS, Orwick S, Lucas DM, Kohlschmidt J, Blum W, Kolitz JE, Stone RM, Bloomfield CD, Byrd JC. Bhatnagar B, et al. Br J Haematol. 2016 Oct;175(2):226-236. doi: 10.1111/bjh.14254. Epub 2016 Aug 1. Br J Haematol. 2016. PMID: 27476855 Free PMC article. - Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, von Lilienfeld-Toal M, Brugger W, Derigs HG, Kremers S, Greil R, Raghavachar A, Ringhoffer M, Salih HR, Wattad M, Kirchen HG, Runde V, Heil G, Petzer AL, Girschikofsky M, Heuser M, Kayser S, Goehring G, Teleanu MV, Schlegelberger B, Ganser A, Krauter J, Bullinger L, Döhner H, Döhner K. Gaidzik VI, et al. Blood. 2013 Jun 6;121(23):4769-77. doi: 10.1182/blood-2012-10-461624. Epub 2013 Apr 30. Blood. 2013. PMID: 23632886 - Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients.
Yuan XQ, Chen P, Du YX, Zhu KW, Zhang DY, Yan H, Liu H, Liu YL, Cao S, Zhou G, Zeng H, Chen SP, Zhao XL, Yang J, Zeng WJ, Chen XP. Yuan XQ, et al. J Transl Med. 2019 Jul 10;17(1):220. doi: 10.1186/s12967-019-1959-3. J Transl Med. 2019. PMID: 31291961 Free PMC article. - DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 Patients.
Yuan XQ, Peng L, Zeng WJ, Jiang BY, Li GC, Chen XP. Yuan XQ, et al. Medicine (Baltimore). 2016 May;95(18):e3519. doi: 10.1097/MD.0000000000003519. Medicine (Baltimore). 2016. PMID: 27149454 Free PMC article. Review. - Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis.
Tie R, Zhang T, Fu H, Wang L, Wang Y, He Y, Wang B, Zhu N, Fu S, Lai X, Shi J, Huang H. Tie R, et al. PLoS One. 2014 Jun 17;9(6):e93353. doi: 10.1371/journal.pone.0093353. eCollection 2014. PLoS One. 2014. PMID: 24936645 Free PMC article. Review.
Cited by
- Significance of targeting DNMT3A mutations in AML.
Huang G, Cai X, Li D. Huang G, et al. Ann Hematol. 2024 Jul 30. doi: 10.1007/s00277-024-05885-8. Online ahead of print. Ann Hematol. 2024. PMID: 39078434 Review. - Effect of DNMT3A R882H Hot Spot Mutations on DDX43 Promoter Methylation in Acute Myeloid Leukemia.
Tabatabaei T, Rezvany MR, Ghasemi B, Vafaei F, Zadeh MK, Zaker F, Salmaninejad A. Tabatabaei T, et al. Biomed Res Int. 2024 May 21;2024:9625043. doi: 10.1155/2024/9625043. eCollection 2024. Biomed Res Int. 2024. PMID: 38807916 Free PMC article. - CD7-positive leukemic blasts with DNMT3A mutations predict poor prognosis in patients with acute myeloid leukemia.
Bai Y, Sun X, Li M, Niu X, Cao W, Niu J, Xiao X, Chen Y, Sun K. Bai Y, et al. Front Oncol. 2024 Mar 21;14:1342998. doi: 10.3389/fonc.2024.1342998. eCollection 2024. Front Oncol. 2024. PMID: 38577341 Free PMC article. - Role of Gene Mutations in Acute Myeloid Leukemia: A Review Article.
Singh H, Kumar M, Kanungo H. Singh H, et al. Glob Med Genet. 2023 Jun 23;10(2):123-128. doi: 10.1055/s-0043-1770768. eCollection 2023 Jun. Glob Med Genet. 2023. PMID: 37360004 Free PMC article. Review. - A novel risk model for predicting early relapse in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem-cell transplantation.
Yuan XL, Lai XY, Wu YB, Yang LX, Shi JM, Liu LZ, Yu J, Zhao YM, Zheng WY, He JS, Sun J, Wu WJ, Zhao Y, Ye YS, Cai Z, Huang H, Luo Y. Yuan XL, et al. Bone Marrow Transplant. 2023 Jul;58(7):801-810. doi: 10.1038/s41409-023-01979-5. Epub 2023 Apr 18. Bone Marrow Transplant. 2023. PMID: 37072477
References
- Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461) Blood. 2002;100:4325–4336. - PubMed
- Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–365. - PubMed
- Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474. - PubMed
- Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18:115–136. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA41287/CA/NCI NIH HHS/United States
- U10 CA031946/CA/NCI NIH HHS/United States
- U10 CA033601/CA/NCI NIH HHS/United States
- U24 CA114725/CA/NCI NIH HHS/United States
- U10 CA101140/CA/NCI NIH HHS/United States
- U10 CA041287/CA/NCI NIH HHS/United States
- P30 CA016058/CA/NCI NIH HHS/United States
- CA77658/CA/NCI NIH HHS/United States
- CA31946/CA/NCI NIH HHS/United States
- R01 CA102031/CA/NCI NIH HHS/United States
- CA140158/CA/NCI NIH HHS/United States
- CA33601/CA/NCI NIH HHS/United States
- P50 CA140158/CA/NCI NIH HHS/United States
- CA16058/CA/NCI NIH HHS/United States
- CA102031/CA/NCI NIH HHS/United States
- CA101140/CA/NCI NIH HHS/United States
- U10 CA077658/CA/NCI NIH HHS/United States
- CA129657/CA/NCI NIH HHS/United States
- CA114725/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical